273 related articles for article (PubMed ID: 28262585)
1. The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma.
van der Kaaij RT; Snaebjornsson P; Voncken FE; van Dieren JM; Jansen EP; Sikorska K; Cats A; van Sandick JW
Eur J Cancer; 2017 May; 76():27-35. PubMed ID: 28262585
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
3. Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
Van De Voorde L; Janssen L; Larue R; Houben R; Buijsen J; Sosef M; Vanneste B; Schraepen MC; Berbée M; Lambin P
Eur J Surg Oncol; 2015 Oct; 41(10):1333-9. PubMed ID: 26091848
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
[TBL] [Abstract][Full Text] [Related]
5. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
6. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
7. A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy.
Dunne B; Reynolds JV; Mulligan E; Kelly A; Griffin M
J Clin Pathol; 2001 Nov; 54(11):841-5. PubMed ID: 11684717
[TBL] [Abstract][Full Text] [Related]
8. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
9. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
[TBL] [Abstract][Full Text] [Related]
10. Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma.
Kathiravetpillai N; Koëter M; van der Sangen MJ; Creemers GJ; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
Eur J Surg Oncol; 2016 Aug; 42(8):1183-90. PubMed ID: 27134188
[TBL] [Abstract][Full Text] [Related]
11. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma.
Blom RL; Sosef MN; Nap M; Lammering G; van den Berkmortel F; Hulshof MC; Meijer SL; Wilmink HW; van Berge Henegouwen MI
Dis Esophagus; 2014; 27(4):380-7. PubMed ID: 24006852
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiation for patients with advanced oesophageal cancer - which response grading system best impacts prognostic discrimination?
Puetz K; Bollschweiler E; Semrau R; Mönig SP; Hölscher AH; Drebber U
Histopathology; 2019 Apr; 74(5):731-743. PubMed ID: 30636069
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.
Li SH; Rau KM; Lu HI; Wang YM; Tien WY; Liang JL; Lin WC
Eur J Cardiothorac Surg; 2012 Dec; 42(6):958-64. PubMed ID: 22466694
[TBL] [Abstract][Full Text] [Related]
15. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
16. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
[TBL] [Abstract][Full Text] [Related]
17. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Curtis NJ; Noble F; Bailey IS; Kelly JJ; Byrne JP; Underwood TJ
J Surg Oncol; 2014 Mar; 109(3):202-7. PubMed ID: 24243140
[TBL] [Abstract][Full Text] [Related]
18. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
[TBL] [Abstract][Full Text] [Related]
19. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis.
Thomas M; Borggreve AS; van Rossum PSN; Perneel C; Moons J; Van Daele E; van Hillegersberg R; Deng W; Pattyn P; Mook S; Boterberg T; Ruurda JP; Nafteux P; Lin SH; Haustermans K
Acta Oncol; 2019 Oct; 58(10):1358-1365. PubMed ID: 31432736
[No Abstract] [Full Text] [Related]
20. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
